UK's NIHR Clinical Research Network's GCP Training Recognized by TransCelerate
Training providers meeting the GCP criteria set out in the guidelines are added to a list of mutually recognized providers. The Clinical Research Network has recently been added to this list. Now, when a study is placed at a site in the NHS, if the Principal Investigator and the research team have completed GCP training provided by the Clinical Research Network, they will not be required to undertake further company-specific GCP training. This will help to streamline study set-up and allow research teams to focus on other important set-up activities such as pre-screening patients.
The National Institute for Health Research (NIHR), under the NHS, Clinical Research Network’s Good Clinical Practice (GCP) training has been added to TransCelerate's list of programs mutually recognized by member companies. TransCelerate members, (which includes companies such as GSK, Pfizer and Roche), have developed guidelines for GCP training standards for research teams – those medical, nursing and clinical support staff delivering the clinical research studies.
Training providers meeting the GCP criteria set out in the guidelines are added to a list of mutually recognized providers. The Clinical Research Network has recently been added to this list. Now, when a study is placed at a site in the NHS, if the Principal Investigator and the research team have completed GCP training provided by the Clinical Research Network, they will not be required to undertake further company-specific GCP training. This will help to streamline study set-up and allow research teams to focus on other important set-up activities such as pre-screening patients.
The full release is located here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
